Progenics Pharmaceuticals, Inc.
|Progenics Pharmaceuticals, Inc. Patent applications|
|Patent application number||Title||Published|
|20140235664||STABLE PHARMACEUTICAL FORMULATIONS OF METHYLNALTREXONE - Stable pharmaceutical compositions useful for administering methylnaltrexone are described, as are methods for making the same. Kits, including these pharmaceutical compositions, also are provided.||08-21-2014|
|20130323286||SYNTHESIS OF R-N-METHYLNALTREXONE - This invention relates to stereoselective synthesis of R-MNTX and intermediates thereof, pharmaceutical preparations comprising R-MNTX or intermediates thereof and methods for their use.||12-05-2013|
|20130216526||METHODS FOR REDUCING VIRAL LOAD IN HIV-1 INFECTED PATIENTS - This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load reducing dose achieves an average maximum decrease of viral load in the subject of at least 1.83 log||08-22-2013|
|20130202618||ANTIBODIES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED INFECTION AND DISEASE - Provided herein are reagents, compositions, and therapies with which to treat||08-08-2013|
|20120136019||(S)-N-METHYLNALTREXONE - This invention relates to S-MNTX, methods of producing S-MNTX, pharmaceutical preparations comprising S-MNTX and methods for their use.||05-31-2012|
|20120009151||Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof - Disclosed herein are novel triazines and related compounds, the synthesis thereof, and compositions, including pharmaceutical compositions, comprising the novel triazines and related compounds. Such novel triazines and related compounds function to inhibit or block entry of viruses of the Flaviviridae family, including Hepatitis C virus (HCV), into cells that are susceptible to virus infection. These compounds are useful for the treatment, therapy and/or prophylaxis of viral diseases and infection, including HCV infection.||01-12-2012|
|20110100099||PREPARATION AND USE OF (R),(R)-2,2'-BIS-METHYLNALTREXONE - This invention relates to synthesis of (R),(R)-2,2′-bis-MNTX, as shown in Formula (I), and related methods and products.||05-05-2011|
|20090047279||(R)-N-Stereoisomers of 7,8-Saturated-4,5-Epoxy-Morphinanium Analogs - Novel (R)—N-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs are disclosed. Pharmaceutical compositions containing the (R)—N-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs and methods for their pharmaceutical uses are also disclosed. Such analogs are disclosed as being useful in treating, among varying conditions, opioid-induced constipation.||02-19-2009|
|20080234306||N-Oxides of 4,5-Epoxy-Morphinanium Analogs - Novel N-oxides of 4,5-epoxy-morphinanium analogs are disclosed. Pharmaceutical compositions containing the N-oxides of 4,5-epoxy-morphinanium analogs and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as modulators of opioid receptors.||09-25-2008|
|20080207669||(S)-N-Stereoisomers of 7,8-Saturated-4,5-Epoxy-Morphinanium Analogs - Novel (S)-N-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs are disclosed. Pharmaceutical compositions containing the (S)-N-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs and methods for their pharmaceutical uses are also disclosed. Such analogs are disclosed as being useful in treating, among varying conditions, hypermotility of the gastrointestinal tract.||08-28-2008|
Patent applications by Progenics Pharmaceuticals, Inc.